PF4 and COVID-19: According to this study, patients who develop thrombotic symptoms after receiving COVID-19 vaccine should be examined for thrombocytopenia, elevated D-dimer, and/or reduced fibrinogen, as well as anti-PF4 ELISA testing in the brain, central venous sinus, and abdomen.